Mizuho Maintains Neutral on GRAIL, Raises Price Target to $100
Mizuho analyst Bradley Bowers maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price target from $65 to $100.
Stocks · News reference
The FDA Posted Briefing Documents For Grails Galleri Test Review Ahead Of The Molecular And Clinical Genetics Panel Of The Medical Devices Advisory Committee That Is Being Held On September 23; Flags No Major Concerns For Co's Cancer Test
https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-23-2026-molecular-and-clinical-genetics-panel-medical-devices-advisory-committee-meeting
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Panel Endorses GRAIL Galleri Cancer Screening Tool
The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, moving it closer to official approval.
Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times
U.S. FDA Advisers Back Safety Of GRAIL's Galleri Multi-Cancer Screening Test; FDA Advisers Vote 6-4 That GRAIL's Galleri Is Effective For Proposed Use In Multi-Cancer Screening Test; Advisers Vote 7-2, With One Abstention, That Benefits Of GRAIL's Galleri Test Outweigh Risks For Proposed Use
https://www.fda.gov/media/194909/download